Frankfurt
14.09.26 | 09:55
4,330 Euro
+0,93 % +0,040
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.08. | PolyPid Ltd. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 12.08. | PolyPid GAAP EPS of -$0.35 beats by $0.03 | 5 | Seeking Alpha | ||
| POLYPID Aktie jetzt für 0€ handeln | |||||
| 12.08. | PolyPid Ltd.: PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results | 1.174 | GlobeNewswire (Europe) | FDA Accepted D-PLEX100 NDA with Priority Review; PDUFA Goal Date of November 28, 2026, Approximately One Quarter Ahead of Previously Communicated Guidance Exclusive U.S. and Canada Commercialization... ► Artikel lesen | |
| 12.08. | PolyPid Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 30.07. | PolyPid Ltd.: PolyPid to Report Second Quarter 2026 Financial Results and Operational Highlights on August 12, 2026 | 7 | GlobeNewswire (USA) | ||
| 29.07. | PolyPid rises as lead product granted FDA priority review | 2 | Seeking Alpha | ||
| 29.07. | PolyPid's NDA For D-PLEX100 Receives FDA Priority Review, Stock Up | 1 | RTTNews | ||
| 29.07. | PolyPid Ltd.: PolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX100 | 610 | GlobeNewswire (Europe) | PDUFA target action date of November 28, 2026, approximately one quarter ahead of Company's previously communicated guidance FDA identified no Filing review issues Acceptance triggers $15 million... ► Artikel lesen | |
| 29.07. | PolyPid Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 22.07. | H.C. Wainwright reiterates Buy on PolyPid stock, $13 target | 3 | Investing.com | ||
| 21.07. | PolyPid, Azurity Pharmaceuticals Agree to Exclusive Commercial Partnership in US and Canada | 6 | Contract Pharma | ||
| 21.07. | PolyPid Partners With Azurity In D-PLEX100 Commercialization Deal Worth Over $320 Million | 1 | pulse2.com | ||
| 21.07. | PolyPid signs $320M deal with Azurity for D-PLEX100 in U.S., Canada | 4 | Investing.com | ||
| 21.07. | PolyPid Ltd.: PolyPid Announces Exclusive Partnership with Azurity Pharmaceuticals for the Commercialization of D-PLEX100 in the U.S. and Canada | 474 | GlobeNewswire (Europe) | PolyPid to potentially receive over $320 million in upfront and milestone payments, including $30 million in upfront and near-term milestone payments, plus tiered royalties ranging from mid-teen to... ► Artikel lesen | |
| 15.07. | PolyPid Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 10.06. | PolyPid Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 01.06. | PolyPid Ltd.: PolyPid Completes New Drug Application Submission to FDA for D-PLEX100 | 220 | GlobeNewswire (Europe) | If approved, D-PLEX100 would address a critical unmet medical need in the prevention of surgical site infections PDUFA target action date currently planned for the first quarter of 2027 PETACH TIKVA... ► Artikel lesen | |
| 01.06. | PolyPid Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 13.05. | PolyPid Q1 2026 Earnings Call: Complete Transcript | 5 | Benzinga.com | ||
| 13.05. | PolyPid GAAP EPS of -$0.35 beats by $0.08 | 1 | Seeking Alpha |
1 2 Weiter >>
34 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 86,35 | +3,48 % | Biotech: Jetzt auf den Rebound setzen! Übernahmegefahr für Evotec und BioNxt, Bayer und BioNTech mit vollen Kassen | Der Biotech-Sektor steht nach einer langen Durststrecke vor einer spektakulären Trendwende, die mutigen Anlegern massive Renditechancen bietet. Denn die Kurse vieler innovativer Hoffnungsträger notieren... ► Artikel lesen | |
| EVOTEC | 2,886 | -2,50 % | Evotec-Aktie: Jetzt auf mehr als +100% Kursgewinn setzen | Die Evotec-Aktie bleibt massiv unter Druck. Aktuell notiert das Papier auf bei rund 3,20 Euro und liegt damit seit Jahresbeginn bei einem Minus von über 40 Prozent. Nach der jüngsten Gewinn- und Prognosewarnung... ► Artikel lesen | |
| VALNEVA | 2,864 | -0,38 % | Valneva: EMA validiert Borreliose-Antrag - Hoffnungsschimmer trotz Umsatzrückgang | ||
| AMGEN | 330,00 | +1,43 % | Milliardenwette geplatzt: Pharma-Aktie kassiert schweren Rückschlag | © Foto: Sebastian Gollnow/dpaNovartis enttäuscht mit Pelacarsen und verliert an der Börse deutlich. Jetzt wächst der Druck auf die Pipeline Enthaltene Werte: US0311621009,US5324571083,CH0012005267Den... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 11,600 | 0,00 % | Wall Street Wire: StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It | Rare-endocrine buyers have paid roughly $2.9 billion and approximately $10.0 billion for acquisitions in this area over the past four months. IMCIVREE, the only approved MC4R agonist for acquired... ► Artikel lesen | |
| OCUGEN | 0,925 | +4,64 % | H.C. Wainwright cuts Ocugen stock price target to $9.50 on trial delay | ||
| VIKING THERAPEUTICS | 27,400 | -0,72 % | Analysts Have a $92 Target on Viking Therapeutics. Here's What Has to Go Right to Get There. | ||
| DEFENCE THERAPEUTICS | 0,280 | -7,28 % | Defence Therapeutics Inc.: Defence Therapeutics CEO Highlights Recent Progress and Outlines Strategic Priorities in Letter to Shareholders | Montreal, Quebec--(Newsfile Corp. - September 8, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 1,115 | -1,33 % | Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026 | Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026
Halle (Saale) / Munich, Germany, August 18, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7)... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,409 | -0,73 % | Hot-Stock: Zuerst der Durchbruch - dann die Rallye! | ||
| ABIVAX | 100,00 | +0,60 % | Goldman Sachs initiates Abivax stock coverage with buy rating | ||
| SAREPTA THERAPEUTICS | 17,740 | +0,57 % | Sarepta Therapeutics climbs 10%, rebounding from recent slide | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,099 | -2,05 % | PacBio Announces Second Quarter 2026 Financial Results | MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2026. Recent Business Highlights Total revenue of $39.0... ► Artikel lesen | |
| IBIO | 1,002 | 0,00 % | iBio auf Wells-Fargo-Gesundheitskonferenz: Pipeline gegen Adipositas nimmt Gestalt an | ||
| ARROWHEAD PHARMACEUTICALS | 71,74 | +0,39 % | Arrowhead Pharmaceuticals, Inc.: Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia | Plozasiran reduced triglycerides (TG) by 79% and 81% versus placebo in SHASTA-3 and SHASTA-4 across the broad sHTG population
More than 90% of plozasiran-treated patients achieved triglycerides... ► Artikel lesen |
Das Unternehmen POLYPID LTD kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +0,93 % bei einem Aktienkurs von 4,330 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu POLYPID LTD finden Sie auf Wallstreet Online.